James Charles Dickerson

8PUBLICATIONS
38CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Econometric and statistical methodsCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillanceMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 25, 2026
Evolving Landscape of Immunotherapy in Melanoma.

|Sep 24, 2025
Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.

James C Dickerson, Jennifer L Caswell-Jin, Fauzia Riaz

|Sep 17, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Fabio Conforti, Federico Merlo, Laura Pala

|Jul 02, 2025
Physician Specialization and Receipt of Updated Breast Cancer Care in the United States: A SEER-Medicare Analysis.

Jennifer L Caswell-Jin, Marissa B Reitsma, Hao Tang

|May 21, 2025
Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.

James C Dickerson, Marcus T Moen, Perry Nielsen

|Feb 12, 2025
Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.

Fauzia Riaz, John L Vaughn, Huili Zhu

Pageof 2

Frequent Collaborators

3 joint publications

Fauzia Riaz

3 joint publications

Jennifer L Caswell-Jin

2 joint publications

Fernando Alarid-Escudero

1 joint publications

Paulette Ibeka